Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|171|4|463-470

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.171, Iss.4, 2015-11, pp. : 463-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2193-2197

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 811-819

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 902-904

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 824-834

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 120-124

John Wiley & Sons Inc

Access to resources Recommend Favorite